Further, the combination of EGFR inhibitor (erlotinib) and GAbsiAXL synergistically enhanced apoptosis and inhibited cancer cell migration, demonstrating that RNA-based inhibition of AXL in the combination of chemotherapies may be beneficial in NSCLC [294]. Here, EGFR is linked to non-small cell lung carcinoma.